
Hepatobiliary and pancreatic imaging
Liver cancer (hepatocellular carcinoma)
Fatty liver, NAFLD, and NASH
Chronic liver disease and cirrhosis
Pancreatic cancer
Technical development in MRI
Quantitative imaging
Education and Training
- M.D., University of Iowa, 2004
Grants
- Prediction and Prevention of Hepatic Decompensation in Patients with Cirrhosis
- A Phase 1b, Open-Label, Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Adult Patients with Presumed Nonalcoholic Steatohepatitis (NASH)
- Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)
- Photon Counting Computed Tomography for Detection of Small Liver Metastases: Comparison to Conventional and Dual-Energy Systems
- BIO89-100-122 - A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BIO89-100 in Subjects with Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)
- A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients with Presumed Nonalcoholic Steatohepatitis
- The imaging objectives of this study are to determine the effect of MGL-3196 on liver PDFF and stiffness (measured by MR Elastography) in a NAFLD population for the following:
- Madrigal MGL-3196-14 "A 52-Week Phase 3 Study of Resmetirom (MGL-3196)
- Imaging Core Lab for Madrigal Protocol MGL-3196-05 (A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis)
- The imaging objective of this study is to determine the effect of MET642 on liver PDFF in patients with nonalcoholic steatohepatitis (NASH).
- CT-868 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Center Study to Evaluate the Efficacy, Safety, and Tolerability of CT-868 Administered for 26 Weeks to Obese Patients wi
- Collaboration for assessment of 129Xe MRI hardware
- Abbreviated MRI for HCC screening in cirrhotic patients